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Abstract
Statistics show a high prevalence of metabolic syndrome (MetS) in patients with mental
illness receiving second-generation antipsychotic medications. MetS is associated with
elevation of obesity, truncal obesity, blood pressure, cholesterol, and fasting glucose.
The purpose of this project was to educate psychiatric providers about the importance of
MetS screening, early detection, management, and referral for better treatment and
management. The project was guided by Lewin’s theory of change model. The project
inquired if educational intervention on MetS improved providers’ knowledge and intent
to adopt MetS guidelines. A literature review and established guidelines of the American
Psychiatric Association and American Diabetic Association about MetS in psychiatric
patients directed the educational content. Five expert panelists with over 10 years of
experience in psychiatric mental health reviewed the educational content using a Likerttype questionnaire. Findings resulted in the acceptance of the educational content without
further recommendation. Twelve staff attended the educational session presented on
MetS. Comparison of the pretest and posttest questionnaires that has 5 multiple choice
questions indicated some positive effects. The good knowledge of MetS, how to screen
for MetS, health promotion activities with consumers, metabolic profile of different
neuroleptic medications, providers’ roles in MetS. The participants’ overall knowledge
about MetS screening improved from 8.3% pretest to 83.3% after receiving the
educational program. The educational project for MetS screening might foster positive
social change by improving continuity and quality of care, which will lead to better
patient outcomes, reduce healthcare cost, and impact positive patient outcomes.
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Section 1: Nature of the Project
Introduction
Patients with chronic mental illness are treated with both first-generation
antipsychotic medications (FGAs) and second-generation antipsychotic medications
(SGAs). The use of psychotropic medications illustrates an essential part of psychiatric
practice. Antipsychotic medications are used in the treatment of mental disorders other
than psychosis, such as bipolar, depression, and anxiety. The use of these antipsychotic
medications has increased the ability of psychiatric providers to treat psychiatric ailments
with tolerable side effects but has given rise to metabolic syndrome (MetS) among
patients with mental illness. The World Health Organization (WHO) has recognized
MetS as a global epidemic and a major public health problem (Ho, Zhang, Mak, & Ho,
2014). Its associated complications are affecting a large number of people. According to
Moore et al. (2017), with the definition of MetS by the International Diabetes Federation
(IDF) and the National Cholesterol Education program, the prevalence of MetS is
estimated at more than 30% in the United States.
Patients with mental illness have an increased risk of developing MetS compared
to the general population (Arms, Bostic, & Cunningham, 2014). MetS is a complication
related to antipsychotic medications used in this vulnerable population. It is considered to
be underdiagnosed and undertreated in psychiatric patients. MetS is associated with
chronic mild inflammation; elevation of obesity, truncal obesity, blood pressure,
cholesterol, and fasting glucose; and increased risk for obesity and truncal obesity, all of
which lead to cardiovascular disease and/or diabetes (Cunningham, Riano, & Mangurian,
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2018; Kioko, Williams, & Newhouse, 2016). Any three of the five components are
necessary for diagnosis (Saloojeel, Burns, & Motala, 2014). According to the American
Heart Association, the rate of MetS in the general population is 34% compared to 55%–
60% in mentally ill patients taking antipsychotic medications (Arms, Bostic, &
Cunningham, 2014). MetS can lead to chronic diseases, such as heart disease and
diabetes, which are responsible for seven out of 10 deaths among Americans each year
and account for 75% of the nation’s healthcare spending (CDC, 2017).
The purpose of this scholarly project is to educate nursing staff and psychiatric
providers about the importance of metabolic monitoring, screening, early detection,
management, and referral of patients to primary care providers for appropriate treatment
and management. Educating nursing staff about MetS and associated complications will
lead to nurses communicating these physical health challenges to patients and
encouraging them to keep medical appointments in order to manage the ailments
properly. The educational intervention will foster social changes through education of
psychiatric providers in order to make a positive impact both physically and mentally on
this vulnerable population.
Problem Statement
MetS is a clustering of cardiovascular risk factors including dyslipidemia,
abdominal obesity, hypertension, and hyperglycemia (Penninx & Lange, 2018). MetS is a
complex, noncommunicable, multiple systems disorder (Cotes et al., 2015). It has
become a serious comorbidity among patients with mental illness. Cotes et al. (2015)
noted that in November 2003, the North American Association for the Study of Obesity,
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American Psychiatric Association (APA), American Diabetes Association (ADA), and
American Association of Clinical Endocrinologists held a conference on antipsychotic
medications and diabetes.
Based on the conference outcome, a class warning was implemented by the APA,
the ADA, and the U.S. Food and Drug Administration related to the risk for diabetics and
recommendations were issued for glucose and lipid monitoring with SGA medications
(Morrato et al., 2016). Because of the increased morbidity in this population, psychiatric
patients taking antipsychotic medications should be screened with the same rate or even
more frequently than patients in the general population. Saloojeel et al. (2014) noted that
these agencies developed a general agreement that established a MetS baseline screening
and monitoring for patients taking antipsychotic medications, mainly SGAs.
I conducted a needs assessment in an in-patient psychiatric center located in the
Midwestern United States to determine the adherence of practice guidelines for MetS
screening by psychiatric providers. The assessment analysis indicated that the gap in
practice was lack of metabolic monitoring and screening among patients taking
antipsychotic medications. Regardless of the global consensus for MetS screening, the
rate of testing remains poor despite the relationship between MetS and antipsychotic
medications (Happell, Platania-Phung, Gaskin, & Stanton, 2016; Kioko et al., 2016;
Munshi, Patel, Mazhar, Hassan, & Siddiqui, 2015). In spite of best practice
recommendations, psychiatrists practicing in this setting were not screening for MetS in
their patients taking antipsychotic medications.
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To address the healthcare gap in practice, providers’ adherence to MetS
guidelines can lead to early identification of treatable metabolic risk conditions,
management, referrals for treatment, improvement in patient quality of life, and reduction
in healthcare costs. I believe that nursing staff are in the position to lead the way in
metabolic control by educating identified patients about behavior changes and healthy
life choices to enhance physical health and associated complications. The guideline
recommends baseline monitoring at the initiation of an SGA, 3 months later, and
annually thereafter. This scholarly project on educating psychiatric physicians and nurses
has the ability to implement the recommended guidelines and to improve the care
provided to people with mental illness taking SGAs.
Purpose
Antipsychotic medications are used in the treatment of mental disorders other
than psychosis, such as bipolar, depression, and anxiety, because of fewer side effects
associated with atypical antipsychotics. There is a long history of using antipsychotic
medications in the treatment of other health problems with or without psychosis. MetS is
one of the undesirable side effects associated with antipsychotic medications. Despite the
benefits of an established protocol and screening tool to monitor MetS, there are
healthcare disparities in screening and treatment of MetS among patients with mental
illness. It should be a realistic expectation for psychiatric providers who prescribe
antipsychotic medications to collaborate with family practice providers to facilitate
appropriate monitoring and treatment for better patient health outcomes.
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The focus of this project is to improve the knowledge of healthcare providers on
the metabolic guidelines for screening, early intervention, and treatment among
psychiatric patients. The goal is to improve patient care by increasing the knowledge of
providers to adopt the best clinical practice guidelines for early detection and treatment of
MetS in this vulnerable population.
The practice focused question is: Does an educational intervention for psychiatric
providers prescribing psychiatric medications improve their knowledge and intent to
adopt and implement metabolic screening guidelines in practice?
Nature of the Doctoral Project
I used several databases for the literature review for this project: MEDLINE, Pub
Med, CINAHL, Google Scholar, and ProQuest. The keywords included in the search
were metabolic syndrome, antipsychotic medications, metabolic screening, and mental
illness. To meet inclusion criteria, the articles chosen were published in the English
language in scholarly, peer-reviewed publications within the past 5 years. I reviewed
guidelines from the ADA, APA, NACE, and North American Association for the Study
of Obesity as well.
The setting for the scholarly project is a stand-alone local psychiatric in-patient
center in the Midwest. The psychiatric center offers comprehensive inpatient psychiatric
services for adolescents, adults, and seniors. The center is staffed by registered nurses
(RNs), three advanced psychiatric nurse practitioners, and three psychiatrists. This
scholarly project was implemented as in-service education for psychiatric providers,
including the RNs, nurse practitioners, psychiatrists, the chief nursing officer, and the
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medical director. I developed the educational materials and then presented to an expert
panel to evaluate the appropriateness of the materials for the staff. The chief nursing
officer and quality assurance manager gave approval to design and implement a 1-hour
educational session with the healthcare team about the ADA recommendations for MetS
screening in patients taking SGAs.
The project question helped to organize the more useful literature search results
and contributed clear guidance in the process of planning, implementing, and evaluating a
practice change in a clinical setting (Curtis, Fry, Shaban, & Considine, 2016). The goal of
staff education is to improve patient care outcomes and achieve a standard of practice. A
30-minutes presentation along with a basic educational pamphlet (see Appendix A) about
MetS, educational intervention objective (see Appendix B), and the ADA/APA consensus
guidelines (see Appendix C) were provided to the team. The M-BACK (pretest and
posttest) questionnaire (see Appendix D) assessed improvement in knowledge. The MBACK is a reliable measure used to assess the effectiveness of interventions aimed at
increasing uptake of metabolic monitoring (Watkins et al., 2017). An additional question
was added to the posttest to ascertain respondents’ likelihood of implementing MetS
screening. Before the educational intervention, the participants completed an anonymous
knowledge pretest. At the end of the educational intervention, the participants completed
the posttest survey (see Appendix E) anonymously.
Significance
The goal of the scholarly project is to improve the knowledge of healthcare
providers on the metabolic guidelines for screening, early intervention, and treatment
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among psychiatric providers prescribing antipsychotic medications. The identified
stakeholders in this project are the mentally ill patients on antipsychotic medications, the
psychiatric providers, the nursing staff, and finally the leadership and policymakers that
influence change in the hospital. The scholarly project will affect different stakeholders
directly and indirectly. The identified stakeholders affected by the scholarly project were
the psychiatric providers with prescriptive authority, the nursing staff, and the
policymakers. The scholar believes that involving the stakeholders is crucial to the
designing and implementation of a successful project. In the case of MetS screening and
monitoring, involving the front-line nurses who will be the ones completing the vital
signs and lab work is imperative. Empowering the frontline nurses to take ownership of
the program is vital for the success of the project. The long-term benefit of monitoring
MetS is for improved health outcomes, wellness, and, reduction in mortality and
morbidity among psychiatric patients taking antipsychotic medications.
Significance to Nursing Practice
Mental illness is not only viewed per severity of the symptoms that are presented
by the individual, it is also how the symptoms lead to impairment in the individual’s
functional ability. Antipsychotic medications noted as the FGAs developed in the 1950s
are the first generation of drugs proven to be effective in treating psychiatric symptoms
and are also used to treat other comorbid psychotic illnesses while SGAs emerged in the
1980s (AHRQ, 2015). Each class of antipsychotic medications has considerable overlap
between them even though they have distinct side-effects profile. According to the
Agency for Healthcare Research and Quality (2015), FGAs are effective in treating
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psychosis but do not adequately improve symptoms of diminished emotional expression,
such as avolition, alogia, and asociality. The FGA medications also produce significant
extrapyramidal side effects such as akathisia, tardive dyskinesia, and neuroleptic
malignant syndrome hyperprolactinemia, avolition, alogia, and anhedonia (AHRQ,
2015). Avolition which means a decrease in motivation. Alogia is diminished speech an
output. Anhedonia is a decrease in the ability to experience a pleasure. Neuroleptic
malignant syndrome (NMS), is a rare but life-threatening side effect of antipsychotic
medication with symptoms of high fever, confusion, rigid muscles, variable blood
pressure, sweating and increased heart rate (Hosseini & Elyasi, 2017).
The atypical antipsychotic medications known as SGAs have a significant
advantage over FGAs and are more efficacious in treating psychiatric symptoms with
more tolerable side effect profiles, improves negative symptoms, and causes less
extrapyramidal symptoms (Xiang, Ungvari, Correll, Chiu, & Shinfuku, 2016). Even
though the medications are known for their efficaciousness, they trigger weight gain,
affect blood glucose and lipid levels, and eventually lead to MetS.
MetS increases among psychiatric patients taking second- generation
antipsychotic (SGAs) medications and increases their risks for physical health issues
including cardiovascular disease, leading to premature morbidity and mortality. The high
mortality rate observed in psychiatric patients is due to comorbid health problems related
to diabetes, stroke, and obesity and all point to MetS. Both atypical and typical
antipsychotic medications have significant risks for MetS in people taking these
medications. However, this monitoring is often neglected, putting these individuals at risk
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for life-threatening complications. Yet, metabolic screening and monitoring remain low
among psychiatric patients on antipsychotic medications putting these individuals at risk
for life-threatening complications. As psychiatric providers prescribe antipsychotic
medications known to have a connection with negative physical health outcomes, there is
a need for them to be proactive and incorporate physical health treatment into their daily
routine.
In today’s healthcare delivery, there is a push to make 90% of clinical decisions
based on best available evidence by 2020 (Warren, et al, 2016). To improve patient safety
and quality of care, it is imperative for nurses to create a culture of evidence-based
practice and base clinical decisions on evidence. Implementation of metabolic monitoring
will improve patient outcomes by closing the gap between evidence and implementation
in a clinical setting. Nurses are the frontline staff and have the potential to influence and
shape healthcare systems in the country. Studies have shown that MetS is associated with
an increased rate of deaths, decreased health outcomes and reduced lifespans among
patients with chronic mental illness. Nurses should take the lead in educating psychiatric
patients about healthy lifestyles that could reduce the risk of development of MetS, and
improve their overall health. Nursing should understand that long-term effects of lack of
metabolic monitoring include increased cost of healthcare spending, morbidity, mortality
rate, chronic illnesses and decreased productivity of the workforce. With the evidence
about MetS more common among psychiatric patients, there is a need to consider
diagnosis and treatment of Mets concurrently with the management of psychiatric
conditions (Penninx & Lange, 2018).
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Implications for Social Change
Studies have shown that MetS is prevalent among psychiatric patients. As a result,
there is a need to consider diagnosis and treatment of MetS simultaneously with the
treatment of psychiatric condition in this population. Cunningham and colleagues (2018)
found that metabolic monitoring aims to address these health disparities by screening for
metabolic parameters and identifying abnormalities so that appropriate interventions will
be implemented. Screening and monitoring of MetS among patients on antipsychotic
medications will not only hinder complexity but will also prevent complications
associated with the illness, improve patient outcome, quality of care and promote positive
social change. Adherence to metabolic monitoring guidelines treatment will improve
continuity and quality of care, which will lead to better patient outcomes, increased
healthcare productivity, and cost effective for United State healthcare system and finally
impact positive patient outcomes in the field of psychiatry. This is alignment with
Walden University’s mission of applying research to solve the programs in the world
(Walden Report, 2017).
Summary
MetS is an emerging problem in healthcare among psychiatric patients taking
antipsychotic medications. MetS is a major and escalating public health challenges
worldwide. The combination of symptoms of high blood pressure, high cholesterol, high
fasting glucose, and truncal obesity that lead to cardiovascular disease and/or a type of
diabetes are associated with Mets. The major contributors to MetS are diabetes mellitus
and hypertension, which are worldwide healthcare problems that affect millions of
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people. The American Diabetic Association (ADA, 2018) reports $327 billion in annual
costs for diabetes costs, which include $237 billion in direct medical costs and $90 billion
in reduced productivity. It is estimated that the number of Americans with prediabetes
will climb from 90.6 million in 2015 to 107.7 million in 2030 (Rowley, Bezold, Arikan,
Byrne, & Krohe, 2017). It is estimated that the global prevalence of diabetes is high, 382
million people with diabetes in 2013, expected to rise to 592 million by 2035 (Forouhi &
Wareham, 2014).
The long-term benefit of monitoring MetS is for improved health outcomes,
wellness, reduction in mortality and morbidity among psychiatric patients taking
antipsychotic medications. Screening for MetS in patients with severe mental illness will
signify an improvement in inequality in healthcare for people with mental illness
(Happell et al., 2016). To decrease morbidity and mortality, early detection, management
and referrals are the long-term benefits of monitoring and screening MetS in this
vulnerable population. Section 2 will address the background and context of this
scholarly educational project.
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Section 2: Background and Context
Introduction
Antipsychotic medications are used in the treatment of mental disorders other
than psychosis, such as bipolar, depression and anxiety, because of the fewer side effects
associated with atypical antipsychotics. MetS is one of the undesirable side effects
associated with SGAs. Regardless of the global consensus for screening and monitoring
MetS, the rate of testing remains poor, despite the clear relationship between MetS and
SGAs (Happell et al., 2016; Kioko et al., 2016; Munshi et al., 2015). In spite of best
practice recommendations, psychiatrists practicing in this setting are not screening for
MetS in their patients who are on antipsychotics.
The focus of the project is to improve the knowledge of healthcare providers on
the metabolic guidelines for screening, early intervention, and treatment among
psychiatric providers prescribing antipsychotic medications. The goal is to improve
patient care by increasing the knowledge of providers and their adoption of best clinical
practice guidelines for early detection and treatment of MetS in this vulnerable
population. The practice focused question was: Does an educational intervention for
psychiatric providers prescribing psychiatric medications improve their knowledge and
intent to adopt and implement metabolic screening guidelines in practice? Use of best
practice guidelines should improve the screening rates and diagnosis/referral for MetS.
Knowledgeable psychiatric nursing care will contribute to the adherence of patients in
addressing self-care.
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In the next section, I will further discuss the concepts, models, and theories; the
relevance to nursing practice; the local background, and the role of the DNP student.
Concepts, Models, and Theories
The Lewin’s theory of change model of 1974 was chosen to guide this project.
Organizational change involves the movement of an organization from its current state to
a desired future state. Lewin’s theory supports changing a traditional pathway of
unfreezing the current provider behaviors (movement) and reinforcing changes in
organizational structure (refreezing). Lewin’s theory supports changing the status quo. It
is used to comprehend how professional behaviors become accepted and continuous in
clinical settings. The theory is a model of organizational change used to guide the design
and implementation of the change process.
Unfreezing is the first stage of implementation of change in an organization. The
theory indicates that involving team members and stakeholders in implementing
interventions and sustaining the project is critical. The transition will face less resistance
if the stakeholders are empowered in authority and responsibility right from the planning
phase. This is the phase of the project where I met with the stakeholders (providers, RNs,
chief nursing officer, and the medical director) to educate them about the need for change
and moving away from their status quo. I was the change agent who educated staff about
the gap in practice. To gain the desired results from the proposed change, leadership
involvement was critical; it became imperative to get their buy-in for the project. They, as
the policy makers, established a clear vision of the change process and reinforced the
benefits of the change to the patients.
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The change phase was the transition phase, which included providing educational
information on the importance of using evidence-based practice guidelines. The
educational goal was to inform the staff about the gap in practice and the importance of
the educational intervention and prescribers’ responsibilities to protect the cardio
metabolic health of the patients and promote better patient outcomes for this population.
Awareness was created about the importance of screening for MetS among patients
taking SGAs. Communication with staff members was imperative at this level in order
for the providers to buy into the idea. If they understood the necessity and urgency of the
behavior, they would be more likely to be receptive toward the change agent.
Involvement of frontline staff from planning to implementation is the most effective
strategy for overcoming resistance to change.
The final phase was the refreezing stage; it is also called the reinforcement phase.
At this phase, an effort was made so that employees adopted the suggested change and
dis not revert to their old ways. At this phase, the staff incorporated the change into their
daily routine by monitoring patients for MetS, obtaining their vital signs, measuring
weight and waist circumference, and obtaining basic lab work. Once MetS were
identified, the providers/nurses should implement care and collaborate with family
practice providers to facilitate appropriate primary care to decrease complications of
chronic illness and reduce the rate of morbidity and mortality.
Key Concepts and Definitions
Table 1 illustrates the defining criteria of MetS according to National Cholesterol
Education Program Adult Treatment Panel and IDF (Sulistiowati & Sihombing, 2016).
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Table 1
Defining Criteria of Metabolic Syndrome
Criteria
Abdominal obesity
Men
Women
Triglycerides
HDL cholesterol
Men
Women
Blood pressure

Fasting blood
glucose

Defining levels
Waist circumference
Greater than or equal to 102 cm (greater than 40 inches)
Greater than or equal to 88 cm (greater than 35 inches)
Greater than or equal to 150 mg (1.7 mmol/L)
Or on medicines for the management of abnormal triglycerides
Greater than 40 mg/dl
Greater than 50mg/dl
Or on medications for the control of abnormal cholesterol
Greater than or equal to 130/85 mmHg
Or on medications for the management of abnormal blood
pressure
Greater than or equal to 110mg/dl
Or on medicines for the management of abnormal blood
glucose

Relevance to Nursing Practice
Ward et al. (2018) noted that poor health outcomes of people with mental illness
are high, which reduces life expectancy by 17 years when compared to the general
population. The life expectancy of people with mental illness is 25 to 30 years less than
the general population (Pena, DeJongh, Haas, & Harms, 2018). According to Liu et al.
(2017), the high mortality in patients suffering from mental illness is largely caused by
preventable and treatable long-term diseases, especially cardiovascular disease. The
adverse metabolic effects of atypical antipsychotics induce more weight gain and
metabolic abnormalities. People with mental illness were 30% less likely to have their
weight, blood glucose, and lipids assessed (Happell et al., 2016). Moreover, 20%–25% of
the world’s adult population has MetS, with higher rates among people with mental
illness (Kioko et al., 2016). Mangurian et al. (2016) suggested that the rates of glucose
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monitoring (fasting blood glucose) and lipids screening are as low as 30% among patients
taking SGAs. Gardner-Sood et al. (2015) studied 450 randomly selected participants in an
out-patient clinic and found that a majority of patients have central obesity, half the
sample had a body mass index greater than 30 kg/m2; 57% were diagnosed with MetS,
and one in five met the criteria for Type 2 diabetes.
In a global study of 311 psychiatric patients taking SGAs, only 3.9% of the
participants had fasting glucose monitoring, 1.8% had a fasting lipid test, and 0% had
monitoring for waist circumference (Saloojeel et al., 2014). In a study of 50 psychiatric
patients treated with SGAs, none had been previously screened for MetS by their
psychiatrists even though 30% were positive for diabetes, 64.4% were diagnosed with
hypertension, and 88% had increased cholesterol (Munshi et al., 2015). In their metaanalysis, Saloojeel et al. (2014) found that in five high-income countries (the United
States of America, the United Kingdom, Australia, Canada, and Spain), routine baseline
screening was above 50% for blood pressure and lipids only, while glucose and
cholesterol were less than 50%.
Regardless of the global established consensus, research shows that the rate of
screening and monitoring MetS remains poor and providers continue to show inadequate
knowledge about MetS (Kioko et al., 2016; Lui et al., 2016). Evidence shows there is a
lack of consistency in education about MetS, which leads to lower rates of screening and
monitoring poor health outcomes for psychiatric patients (Łopuszańska et al., 2014;
Munshi et al., 2015).
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Gaps in Practice
A survey by Munshi and colleagues (2015) showed 50 psychiatric patients taking
SGAs in a Canadian psychiatric hospital did not get screened for MetS syndrome. The
outcome of the survey showed that the psychiatrists fail to conduct a complete MetS
screening on the patients, even though the patients were positive for MetS. The ADA
consensus guideline is still in place today. It still remains the responsibilities of
psychiatric providers to follow the ADA recommended guidelines for MetS screening in
patients taking SGAs (Gardner-Sood et al., 2015; Lopuszanska et al., 2014). Education
still remains one of the factors for improving the rate of metabolic screening (Castillo et
al., 2015).
Evidenced-based practice has become the cornerstone for healthcare practice. The
scope and standards of psychiatric nursing is defined as a holistic approach involving the
physical, mental, psychosocial, and spiritual needs of the patients (APNA, 2014). For
nurses to provide the best practice, they are challenged to search for the best evidence to
support patient assessment, intervention to develop policies and to refine old ones. With
evidence-based practice, doctorally prepared nurses are situated to fill the gap that has
developed in the healthcare system to serve those with mental illness who are at risk of
adverse health outcomes (Bolton, Knight, & Kopeski, 2016). The Institute of Medicine
(IOM) noted the gap between what we know and what we do in patient care. Nurses have
the responsibility to bridge the research-practice gap. Even though there exists a practice
guideline for metabolic monitoring of patients with mental illness taking antipsychotic
medications, the monitoring in low in this population. Health promotion, prevention of
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illness, and management of chronic diseases are some of the primary functions of
doctorate-prepared nurses according to American Nurses Association (ANA, 2017).
The life expectancy and quality of life for people with mental illness will not
improve if metabolic effects of antipsychotic medications go undetected. Screening for
MetS in patients with mental illness will signify an equality in healthcare for people with
mental illness (Happell et al., 2016). According to Cunningham and colleague (2018),
implementation of MetS monitoring and screening addresses the health disparities among
psychiatric patients so that appropriate interventions will be implemented for effective
positive and social changes to improve patient outcomes. Lack of transforming guidelines
into practice as seen in the lack of utilizing the MetS screening tool among psychiatric
patients on SGA will prevent early diagnosis and treatment of MetS (Kioko et al., 2016).
The project established a scholarly evidence-based project that supported the significance
of screening and monitoring MetS in patients taking SGAs to improve patient outcomes
by closing the gap between evidence and implementation in a clinical setting.
Barriers to Screening and Monitoring
Even though the evidence-based practice has shown to improve quality of care
and patient outcomes, yet, there exist some barriers to implementation of research
evidence in clinical practice. The application of evidence-based is not a linear process; it
comprises many steps and relationships the between researcher and the knowledge users.
Human beings are resistant to change in general. Change in any setting is often faced
with resistance and can be challenging in nature. Despite the benefits of using screening
tools to monitor MetS, barriers to screening still exit. The lack of adequate screening and
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management of MetS is an indication that there are barriers to a successful
implementation of the screening and monitoring of patients taking antipsychotic
medications. There are three levels of barriers identified, which include providers,
patients, and hospital.
Providers’ Barriers
One of the major reasons associated with providers’ barriers in the
implementation of MetS screening and monitoring according to the established guideline
is the inadequate knowledge about the screening. It was important that the healthcare
providers became conversant with about the metabolic screening and monitoring process.
Munshi and colleagues (2015) noted that psychiatric providers are not trained to provide
basic primary care to psychiatric patients. Pena, DeJongh, Haas, & Harms (2018) stated
that psychiatric providers have inadequate knowledge and awareness about the risk of
MetS associated with SGAs. According to McKenna and colleagues (2014), there exists
some confusion regarding who is responsible for screening MetS. Edelsohn and
colleagues (2015), found that metabolic monitoring can be affected by a lack of obvious
designated responsibility for recognizing and managing physical health problems and
lack of integrated services.
Some psychiatric providers believed that it is not within their scope of practice to
screen and manage MetS, while PCPs stated it was the responsibility of the psychiatric
providers to monitor MetS in psychiatric patients. Another vital factor identified by
psychiatric providers’ poor adherence to established guidelines was an insufficient
provider time in performing the assessment, interpreting lab values and educating patients
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(Jeffrey, 2015). Poor communication between mental healthcare providers and primary
care providers can lead to negative health outcomes associated with poor laboratory
monitoring (Edelsohn, Parthasarathy, Terhorst, Karpov, & Schuster, 2015).
In a study by Mangurian and colleagues (2013), over 150 primary providers were
surveyed; 100 reported that they believed it was the responsibility of the mental health
provider to test for MetS in psychiatric patients taking SGAs. Education of psychiatric
providers, PCPS, and frontline nurses is imperative to understand the importance of
screening, monitoring, and management of MetS (Cohn, 2013).
Patients’ Barriers
Failure to receive metabolic testing was most strongly associated with severity of
psychiatric illness, patient characteristics such as cognitive dysfunction, lack of insight,
judgment, delusions, hallucinations, paranoia and chronic mental illness (Morrato et al.,
2016). Patients may not be compliant with blood work, blood pressure checks, and
height, weight and waist circumference measurement due to a lack of insight, poor
judgment, delusions, hallucinations, and aggressive behavior. The mental health patients
may lack the insight into the relationship between their mental and physical conditions,
and as a result, may be less likely to recognize their symptoms and are less likely to seek
medical help.
Psychiatric Center’s Barriers
Some mental health facilities are not equipped with resources needed to carry out
the screening such as a weight scale, a blood pressure monitoring kit, and a tape measure.
Munshi and colleagues (2015) indicated that another barrier hindering continuous
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monitoring of MetS is the lack of integrated care between mental health and primary
care. The patients often go from mental health provider to primary care, therefore
incurring cost and at times may be lost in the healthcare system. Jeffery (2015) found out
that limited access to primary PCPs and a poor referral system led to inadequate
compliance by staff and patients in regard to lab work and any other recommendations.
Most of the psychiatric patients are covered under Medicaid, with limited providers
accepting patients with Medicaid, which increased their wait time for an appointment and
thereby impeded continued monitoring.
Guidelines for Management of Metabolic Syndrome
According to Morrato and colleagues (2016), a decade ago, the American
Diabetes Association (ADA), APA, American Association of Clinical Endocrinologists,
and the North American Association for the Study of Obesity convened a conference on
the subject of antipsychotic drugs and diabetes. The FDA established class warnings
about an increased risk for hyperglycemia and diabetics with SGAs (Cotes et al., 2015).
Around the same time, the ADA, APA, American Association of Clinical
Endocrinologists, and North American Association for the Study of Obesity developed a
consensus that recommended baseline screening and monitoring of metabolic risk for
patients taking SGAs (Saloojeel et al., 2014; Cotes et al., 2015). The diagnosis of MetS
included: increased waist circumference, raised blood pressure, increased triglycerides,
decreased high-density lipoprotein (HDL) cholesterol and raised plasma glucose
(Saloojeel et al., 2014). According to Ward and colleagues (2018), the guidelines
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recommended that all patients prescribed antipsychotic medications should have
metabolic screening completed every 3 months.
Guidelines for Metabolic Monitoring
According to Cotes and colleagues (2015) guidelines for the management of
patients taking antipsychotic medications. The recommendations are, Baseline,
assessment of personal, and family history, blood pressure, weight, waist circumference,
fasting lipids, blood glucose,
Measure weight at 4 weeks and 8 weeks
Repeat labs at 12 weeks and yearly afterwards.
The guideline outlines the frequency of screening and all the necessary
monitoring parameters that will guide mental health providers for screening, monitoring,
diagnosing and treating of MetS in patients taking antipsychotic medications especially
SGAs. Early screening of patients will help meet the Institutes of Medicine (IOM)
objectives for health improvement, which are safety, timeliness, efficiency, effectiveness,
equitable and patient-centered care (IOM, 2016).
The defining criteria for MetS is established by National Cholesterol Education
Program Adult Treatment Panel (ATPIII) and IDF (Sulistiowati & Sihombing, 2016).
The diagnosis of MetS is met when 3 of the 5 criteria; increased waist circumference,
increased blood pressure, increased triglycerides, decreased high-density lipoprotein
(HDL) cholesterol and raised plasma glucose are present in an individual (Saloojeel et al.,
2014). Once the diagnosis or risk factor is identified, appropriate treatment modality
should be initiated. Treating both psychiatric disorders and MetS is imperative to enhance

23
better treatment outcomes for both conditions by referring patients to appropriate
providers. As prescribers of antipsychotic medications, is imperative to be aware of
specific psychotropic medications that raise the MetS risk more than others do and to be
able to adapt the prescription of a particular medication to the cardiovascular risk profile
of patients (Penninx & Lange, 2018). It is vital for nurses to educate predisposed
psychiatric patients to MetS unhealthy lifestyle such as smoking, excessive alcohol intake
and their contributions to poorer cardiovascular health and an increased risk of MetS.
Follow-Up Monitoring for MetS
According to Table 2, if abnormality is noted in any of the parameters, there are
different treatment options to choose from; switch to a less risky agent, decrease the
dosage of the medication, discontinue the medication, recommend healthy life style
changes, and make referral for diabetes, lipid and weight management. Table 1 illustrated
the recommended guidelines for baseline and continues monitoring of MetS.
Local Background and Context
The setting for the scholarly project is an in-patient urban psychiatric Center
located in the Midwestern part of the country. The Center has three psychiatrists, three
psychiatric nurse practitioners (NP), and many RNs. The hospital has other departments
such as social work, psychology, and counseling. The medical director is a psychiatrist
who oversees the clinical operations of the hospital and policy development. The
psychiatrists and NPs are the ones that diagnose, treat, and discharge patients in this
hospital. The setting is a 60-bed acute care psychiatric Center that treat adolescents,
adults and seniors. The Center has discharges and admissions on a daily basis. On a
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typical day; they discharge at least five patients and admit five new patients. The RNs are
responsible for taking care of the patients on the unit. Most of the patients are low
income, uninsured, underinsured, and rely on Medicaid coverage. The population seen in
this psychiatric Center is diverse but predominantly from minority groups.
The Center does not have any established protocol for monitoring MetS on
patients that are taking antipsychotic medications. Regardless of the recommendations,
metabolic disorders are still under-diagnosed and most of the time ineffectively treated in
patients with mental illness (Munshi et al., 2015; Kioko et al., 2016). The prevalence of
MetS among this population increased their risks of morbidity and mortality compared
with the general population. According to Richardson, Lee. Kalarchian, & Ren, (2016),
31% to 34% of the mentally ill population die from cardiovascular disease as a result of
MetS. In a study of 50 psychiatric patients who were treated with SGAs, none of these
patients had been previously screened for MetS by their psychiatrists even though 30%
were positive for diabetes, 64.4% were diagnosed with hypertension, and 88% had
increased cholesterol (Munshi et al., 2015). Adequate monitoring of MetS and its
associated complication is necessary among psychiatric patients taking antipsychotic
medications to reduce the occurrence of MetS.
In this local psychiatric Center, a large number of patients on antipsychotic
medications meet the criteria for MetS. One of the identified issues is lack of knowledge
and who should monitor the MetS. The psychiatric providers are counting on the family
practice to monitor for MetS. It is the providers’ responsibility for prescribing SGAs
along with monitoring the metabolic abnormalities associated with the medications. The
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goal of the educational intervention is to educate the psychiatric providers and nursing
staff about the importance of early detection and intervention to alleviate these health
problems associated with MetS.
Role of the DNP Student
It is a challenging and complicated process to bring evidence-based practice to
clinical practice. The best quality evidence will be of no use unless incorporated into
clinical practice. Improvement in healthcare outcomes and reduce cost of healthcare
spending will be achieved with patients receiving evidence-based care. The
organizational and systems leadership by nursing plays an integral part in the
implementation of evidence-based practice in healthcare and is vital in creating an
effective team to enhance the quality care and safety of their patients. As noted in AACN
(2006), the mission of Walden University is to produce doctorally-prepared nurses with
the knowledge and skills to positively lead the nursing profession in producing
quality patient outcomes. The American Association of Colleges of Nursing (AACN,
2006) endorsed a need to enhance knowledge to improve nursing practices and patient
outcomes; this coincides with Walden’s social change, which implies that a positive
social change results in the improvement of human and social conditions. Improved
competencies for increasingly complex clinical, faculty, and leadership roles; advanced
leadership skills, and clinical instruction by AACN (2006) coincides with Walden
University visions of positive change in advancing greater global health. The scholarly
project is aligned with the AACN (2006) goal and that DNP prepared nurses have the
knowledge and skills to eliminate health disparities and to promote patient safety and
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excellence in practice. The DNP graduates are able to assess risk and collaborate with
others to manage risks ethically, based on professional standards. Adherence to mental
health treatment will improve continuity and quality of care, which will lead to better
patient outcomes, increased healthcare quality, and cost-effectiveness for the United
States healthcare system. I hope to use the knowledge to influence positive patient
outcomes in the field of psychiatry. The determination of the need for this educational
intervention occurred through a needs assessment during my clinical rotation, which took
place at the unit through collecting and reviewing data.
At the same time, I wanted to understand the providers’ viewpoint of metabolic
screening because, regardless of the agreed upon guideline. The rate of screening remains
low and the long-term effects on patients’ health are being ignored. It was noted that the
providers did not order baseline blood work; staff nurses do not obtain vital signs, weight,
height and waist circumference prior to initiation of SGAs in psychiatric patients. I
approached the chief nursing officer and the medical director, who is a psychiatrist, about
the identified problem of not following the established MetS monitoring guideline in the
Psychiatric Center. The overall goal of the DNP student was to educate the psychiatric
providers about the relevance of MetS screening and monitoring in mentally ill patients
taking antipsychotic medications. Early detection is vital to lower cardiovascular risk and
to improve patient health outcomes. The DNP project intervention was to present
education to psychiatric providers via PowerPoint with the objective of increasing their
knowledge and identification of MetS in this vulnerable population for better health
outcome.
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Summary
SGAs are used to manage different psychiatric conditions even though they have
the tendency to cause weight gain, which predisposes patients to altered glucose and lipid
metabolism leading to MetS. There is a globally recommended guideline for screening
and monitoring of patients prescribed SGAs for MetS. Despite the screening and
monitoring in Psychiatric Centers.
The focus of this project was to educate providers and staff on using the best
practice guideline that will improve the screening of patients on SGAs for MetS and to
improve health outcomes of patients who have mental illness. According to the AACN
(2006), “integration of these new or refined skills improves outcomes through
organizational/systems leadership, quality improvement processes, and translation of
evidence into practice (pp. 10). The DNP educational intervention supports nursing
scholarship by initiating a change process in the organization based on research evidence.
It integrated patient outcomes and safety as the driving forces in quality and patient
satisfaction was aimed at education regarding the importance of screening and
monitoring for MetS in patients taking SGAs in order to improve patient outcomes by
closing the gap between evidence and implementation in a clinical setting.
Section 3 will review the plan for collection and analysis of evidence.
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Section 3: Collection and Analysis of Evidence
Introduction
SGAs are used in the treatment of mental disorders other than psychosis, such as
bipolar, depression, and anxiety, because of fewer side effects associated with atypical
antipsychotics. MetS is one of the undesirable side effects associated with antipsychotic
medications. Regardless of the global consensus for screening and monitoring MetS, the
rate of testing remains poor, despite the relationship between MetS and antipsychotic
medications (Happell et al., 2016; Kioko et al., 2016; Munshi et al., 2015). In spite of
best practice recommendations, psychiatrists practicing in this setting are not screening
for MetS in their patients prescribed SGAs.
The focus of the intervention was to improve the knowledge of healthcare
providers on the metabolic guidelines for screening, early intervention, and treatment
among psychiatric providers prescribing antipsychotic medications. The goal was to
improve patient care by increasing the knowledge of providers and their adoption of best
clinical practice guidelines for early detection and treatment of MetS in this vulnerable
population. The practice-focused question was: Does an educational intervention for
psychiatric providers prescribing psychiatric medications improve their knowledge and
intent to adopt and implement metabolic screening guidelines in practice? Use of best
practice guidelines should improve the screening rates and diagnosis/referral for MetS.
Knowledgeable psychiatric nursing care will contribute to the adherence of patients in
addressing self-care.

29
The goal of the educational intervention was to increase adherence to metabolic
screening by healthcare providers. According to the National Health Service, brief
educational interventions are a common method to engage nurse practitioners in thinking
about ways to change their practice to improve health outcomes for patients (White,
Hemingway, & Stephenson, 2014). The implementation of evidence-based metabolic
screening will be the cornerstone for improving future care for psychiatric patients.
Practice-Focused Question
The project will improve the care provided to mentally ill patients taking
antipsychotic medications by improving screening rates, diagnosis, and referral of MetS.
The practice-focused question is: Does an educational intervention for psychiatric
providers prescribing psychiatric medications improve their knowledge and intent to
adopt and implement metabolic screening guidelines in practice?
Program Design
The purpose of the scholarly project was to educate and improve the knowledge
of healthcare providers on the metabolic guidelines for screening, early intervention, and
treatment for psychiatric patients prescribed SGAs. The education included an
established screening tool from the Missouri Department of Mental Health for MetS (see
Appendix F). The guideline outlined the frequency of screening and all the necessary
monitoring parameters that will guide mental health providers in screening, monitoring,
diagnosing, and treating MetS in patients taking SGAs. The project is not connected to
patients directly. It is about educating healthcare providers on the use of the tool to
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implement the treatments and reduce the MetS risk and subsequent diseases among
patients with severe mental illness.
The setting for the project was an in-patient acute care psychiatric center that
targets an adult population. The population for this project was the psychiatric providers
and registered nurses caring for mentally ill patients taking SGAs. Staff education was
provided to healthcare providers that included three psychiatrists, three psychiatric nurse
practitioners, and registered nurses. The staff were given the option to participate in the
educational intervention (see Appendix A) and complete the pretest, posttest assessment
(Appendix D) at the end of the intervention. Permission from Andrew Watkins to use the
survey is shown in Appendix G. The pretest consisted of five multiple-choice questions
about the content of the educational intervention and the questionnaire designed for the
prescribers to solicit if they monitor their patients for metabolic abnormalities. An
evaluation questionnaire was geared toward the importance of the education to their
practice. At the end of the educational presentation, participants were required to
complete the posttest, which was a duplication of the pretest and the post-evaluation
survey (see Appendix E).
Sources of Evidence
Several databases were used for the literature review including MEDLINE, Pub
Med, Psych INFO, Nursing, and Allied Health database, and CINAHL and Google
Scholar. In reviewing literatures, particularly in patients taking antipsychotic
medications, the keywords included, metabolic syndrome, antipsychotic medications,
metabolic screening and mental illness, obesity, and diabetes. In other to meet the
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inclusion criteria, the articles chosen for the project were published in English language,
scholarly, peer reviewed journals within the last 5 years. For the literature review, a total
of 30 articles were identified and examined. The providers and the nursing staff were
taught by PowerPoint and verbal presentation about the prevalence, risk factors and
implications of MetS in patients with mental illness. The education was delivered on-site
to providers and nursing staff. Prior to the presentation, the educational flyer (see
Appendix H) was disseminated to the healthcare staff via e-mails a week before the
presentation. The educational intervention included information on the rationale for
obtaining BMI, weight, height, required labs, and a referral to a PCP when patients are
prescribed SGAs.
Data Collection
The data for the DNP project will be collected from the psychiatric providers
using the pretest/posttest M-BACK questionnaire (Watkins et al., 2017) to evaluate the
educational module for MetS risk factors, screening, monitoring, early intervention and
referral for treatment. The M-BACK questionnaire is a reliable tool to measure
practitioners’ barriers, knowledge and confidence regarding MetS screening in patients
with mental illness (Watkins et al., 2017). The panel of experts are had over 10 years of
experience in caring for psychiatric patients and they included a nurse educator, a nurse
manager, two nurse practitioners and a psychiatrist. A comparison was made to determine
the likelihood of the providers screening and monitoring for MetS in their clinical setting
after attending the educational session. The surveys were anonymous and are being kept
in a locked drawer.
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Descriptive statistics were used in analyzing the data. The education was
presented to the nursing staff during their staff meeting as recommended by the expert
panel.
Protections
The educational session was held at a local psychiatric Center in the Midwest.
There is no disclosure of the participating providers or their place of practice. A consent
from the chief nursing officer for project implementation was obtained by me. Patients
were not part of the project and there was no risk to healthcare providers attending the
educational intervention. The psychiatric providers and the registered nurses had a choice
to participate and complete the pretest, posttest and evaluation survey, which implied
consent. The Walden University Institutional Review Board (IRB) approved the project
(IRB approval # 05-21-19-0761020) prior to project implementation. There was no
compensation for attending the educational session; rather, I provided snacks to the
participants to show appreciation. The completed pretest, posttest, and evaluation surveys
will be stored in accordance with IRB requirements and kept confidential in a locked box.
Individual responses on the surveys were anonymous.
Analysis and Synthesis
The data from the survey were analyzed using descriptive analysis. The goal of
the project was to educate the healthcare providers about the implementation of metabolic
screening (MetS) based on current guidelines, including referring patients to primacy care
providers for treatment of Mets if needed. A pretest and posttest were administered to
providers to determine knowledge of metabolic screening guidelines before and after the
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educational intervention. The pretest took at least 5 minutes to complete. A MetS
pamphlet (see Appendix A) along with MetS screening tool was provided to participants
based on established MetS screening guidelines. After the educational intervention, a post
survey, which focused on the information presented in education and handout about MetS
was provided to the participants. After collecting the pretest, the PowerPoint educational
intervention (see Appendix I) was provided in a 30 minutes period succeeding a 15
minutes period for questions and answers.
Summary
SGAs are widely used in the management of different psychiatric conditions
because the medicines are effective in managing psychiatric symptoms with more
tolerable side effects. However, antipsychotic medications have a weight gain tendency,
which predisposes patient to altered glucose and lipid metabolism resulting in MetS.
MetS is a combination of risk factors that put an individual at risk for cardiovascular
diseases, which are the leading cause of premature death in the United States. There is a
globally recommended guideline for screening and monitoring of patient on MetS.
Despite the screening and monitoring guideline, there is a continued lack of screening
and monitoring of patients taking antipsychotic medications in Psychiatric Center. The
focus of this project was to develop recommended strategies to improve the screening of
patients on antipsychotic medications for MetS and to improve health outcomes of
patients who have mental illness. The educational intervention for providers about the
importance of screening for MetS was cost-effectiveness as early identification and
treatment of chronic diseases may avoid future complications and resulting costs. Section
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4 describes the findings from the five expert panelists, and the findings and
recommendations derived from the analysis of the educational project.
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Section 4: Findings and Recommendations
Introduction
The local problem identified for this scholarly project was lack of adherence to
practice guidelines for MetS screening and monitoring by psychiatric providers. The gap
in practice was lack of metabolic monitoring and screening among psychiatric patients
taking antipsychotic medications. Regardless of the global consensus for MetS screening
and monitoring, and despite the relationship between MetS and SGAs, the rate of testing
remains poor (Happell et al., 2016).
The association between antipsychotic medications and MetS is complex. As the
literature review revealed, MetS can lead to chronic diseases, such as heart disease and
diabetes, which are responsible for seven out of 10 deaths among Americans each year
and account for 75% of U.S. healthcare spending (CDC, 2017). The education will
improve patient care by increasing the knowledge of providers and their adoption of best
clinical practice guidelines for early detection and treatment of MetS in this vulnerable
population. The purpose of this DNP project was to implement an educational
intervention to educate healthcare providers about the importance of MetS among
patients taking SGAs.
Findings and Implications
The setting for the scholarly project was an in-patient psychiatric center in the
Midwest. The MetS toolkit (see Appendix F) was created to provide participants with a
handout on critical information regarding MetS intervention. Five expert panelists were
selected to review the educational content and provide feedback using a Likert-type
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questionnaire. The selected five expert panelists chosen for the educational material
review comprised of one psychiatrist, two psychiatric nurse practitioners, one nurse
educator, and one charge nurse. The chosen panel of experts had over 10 years of
experience in psychiatric mental health. The Likert-type questionnaire (see Appendix D)
was used by the expert panelists in reviewing the educational contents. The questionnaire
included five questions with the following answer options: strongly agree, agree, neutral,
disagree, and strongly disagree. The sixth question was an open-ended question for
comments or recommendations.
The educational material (see Appendix I) was presented to the five panelists for
their appraisal and recommendations. The expert panelists were given the opportunity to
review the educational content for relevance to patient care and usefulness to the
psychiatric center. The findings of the panelists indicated the contents about risks
associated with MetS were easy for providers to understand, and the contents met the
educational objectives (see Appendix B) of the project. The findings from the
intervention resulted in the acceptance of the educational content by the panel of experts.
The experts did not make any further recommendations.
The educational intervention may result in improved outcomes for psychiatric
patients taking SGAs. The organization may benefit by incorporating the education into
annual staff training, which may lead to an increase in referrals for metabolic follow-up
to other specialties of the organization if the program is successful. The major implication
is the reduction in healthcare costs, prevention of chronic illnesses, and improvement in
the quality of life for psychiatric patients.
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Table 2
Results of the Expert Panelist Questionnaire
Questionnaire Item
Do the planned educational materials meet the
objectives of the project?
The educational content is simplified for providers’
understanding.
Will the educational content improve providers’
knowledge about the importance of metabolic screening
among psychiatric patients taking antipsychotic
medications?
Will it be beneficial to make the education content part
of providers’ annual training?
The measure of providers understanding of the
education content will be measured by the outcomes of
the posttest.

SA
5
100%
5
100%
5
100%

Response
A N
D

SD

5
100%
5
100%

Note: N = 5; SA = strongly agree, A = agree, N = neutral, D = disagree, SD = strongly
disagree

Implementation
A total of 12 participants attended the educational session presented to staff on
MetS. The participants comprised of three psychiatrists, a psychiatric nurse practitioner,
one nurse educator, six RNs, and one psychiatric technician. Both pretest and posttest
questionnaires were identical and they used a 5-point Likert scale in which the
participants were asked to circle the appropriate answer to indicate their chosen response
to the questions. This process gave me the opportunity to determine the participants’
changes in knowledge before and after participating in the educational intervention. The
staff members were informed that participation in the educational project was voluntary.
Before the educational presentation, a pretest M-BACK Likert-type questionnaire (see
Appendix D) was given to the participants, which took about 5 minutes to complete.
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After collecting the pretest from the participants, the educational intervention was
presented via PowerPoint presentation (see Appendix I). The presentation lasted about 30
minutes and was followed by a period for questions and answers. The posttest
questionnaire (see Appendix D) focusing on the educational information and making a
change in practice, the MetS screening form (see Appendix F), and the ADA–APA
consensus guidelines (see Appendix C) were provided to the participants.
Table 3
Pretest and Posttest Intervention Results about MetS, n =12, (in percentage)
Question
I have good knowledge of MetS.
I understand how to screen for MetS.
My work prevents me from doing any health promotion activities
with consumers.
I understand the metabolic side effects profile of different
neuroleptic medications.
Metabolic health screening is an important part of my role as a
mental health clinician.
Note: N = 12

Pretest
8.3%
16.7%
33.3%

Posttest
83.3%
75.0%
41.7%

25.0%

66.7%

25.0%

75.0%

Descriptive Data Analysis
Upon reviewing the results of the data collected from the educational intervention
of pretest and posttest. Based on the small sample size of the study, the result of the
responses was entered in a table format. In observing the answers between the pretest and
posttest to determine whether the answers changed after the educational program which
shows a significant change. The following represents the presentation of the results and
findings.
Before the educational program, question #1 statement “I have good knowledge
of MetS,” the pretest answers showed 8.3% of the participants strongly agreed. After the
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educational intervention, the posttest showed 83.3% of the participants strongly agreed
with the statement. The result showed the effectiveness of the educational intervention.
Please refer to table 3 for comparison of the pretest and posttest scores. In response
question 2 statement, “I understand how to screen for MetS? 16.7% of the participants
strongly agreed before the educational intervention and 75.0% of the participants strongly
agreed after the educational intervention. The third prompt related to whether their work
prevented them from doing any health promotion activities with consumers. The
responses on the pretest and posttest were similar with 33.3% of the participants agreeing
before the educational intervention and 41.7% agreeing after the educational intervention.
The question may have been confusing because it did not specify physical activity. If the
participants perceived physical activity to be workout exercise, it would likely influence
their responses. The responses may have resulted from lack of question clarity. The
fourth prompt related to understanding the metabolic side effects profile of different
neuroleptic medications. Based on the analysis, the overall response of the participants
indicated an improvement in knowledge about metabolic side effect profiles after the
educational intervention, with 25.0% strongly agreeing on the pretest and 66.7% strongly
agreeing on post education. The fifth prompt related to the role of healthcare clinicians in
metabolic screening. Based on the analysis, the participants’ knowledge improved about
the importance of metabolic health screening as part of their roles. The pretest number of
participants who strongly agreed with the statement improved from 25.0% to 75.0% on
the posttest. The overall result showed the effectiveness of the educational intervention.
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Implications to Positive Social Change
According to Aselton, Joerg, and Affenito (2013), doctorate-prepared nurses
(DNP) are in the position to influence health policies which will lead to a significant
transformation in the healthcare system. One of the objectives of the clinical preventive
services is to reduce the rate of disability, cost of healthcare, death and improve the
health of the nation. The clinical preventive services are important to accomplish the
“Healthy People” national the goal, which is promoting the health outcome of the nation.
In alignment with the national calls for action and the need for health promotion and
disease prevention, The DNP prepared nurses are in the position to utilize prevention and
population health principles in inter-professional teams to effects health outcomes. The
Psychiatric Center can use the project as a reference to develop providers’ annual training
on MetS. It will lead to a greater awareness among nursing staff about the importance of
monitoring for hypertension in each patient that attends the Psychiatric Center. The
longer-term implication of the educational study is that monitoring of MetS in psychiatric
patients taking anti-psychotic medications will prevent complications associated with
MetS, improve patient the outcome, reduce healthcare cost, and finally impact positive
social change in the field of psychiatry.
Recommendations
The outcome of the questionnaires strongly suggests that the educational
intervention had an effect on the providers’ knowledge level and their willingness to
screen for MetS on psychiatric patients taking antipsychotic medications. The registered
nurses clearly understand their role and ability to help patients that may be at risk for
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MetS by encouraging them to be compliant with lab draws, counseling them on physical
activity and a healthy diet for weight. From the results of the DNP project, few
recommendations for psychiatric providers in MetS screening and monitoring were
noted. For all psychiatric providers working at the Psychiatric Center, educational
programs specific to MetS screening and monitoring need to be provided annually to staff
by the education department. This education needs to include not only screening and
monitoring but also early intervention, collaboration, and referral to expert providers.
Second, evidence-based guidelines and tools need to be adopted by the psychiatric
providers to help manage MetS among these vulnerable population. This project shows
that continuous education is critical for providers to be abreast with new research in
healthcare for better patient outcomes. Third, the nursing staff should endeavor to obtain
the necessary lab work and vital signs when ordered by the providers. Fourth, considering
monotherapy once the risk factor is identified if a patient in on more than one
antipsychotic medication, switching to medication with less weight gain profile.
Strengths and Limitations of the project
Strengths
There are several strengths and limitations to my DNP scholarly project. One of
the major strengths of the project is that the educational project was developed based on
currently available evidence and established global consensus for the management of
MetS among people with mental illness. One strength for the implementation of the
educational project was the support from the frontline registered nurses who worked on
the unit. The frontline nurses who participated in the educational intervention acquired
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some knowledge about MetS which will affect their nursing practice in a positive
manner.
Limitations
There were several limitations to this educational project which include, a
convenience sample of 12 participants was utilized for the educational project; as a result,
the conclusion cannot be generalized. According to Faber, & Fonseca (2014), a small
sample size of 12 participants might not be able to be generalized to the general
population. The posttests were given immediately after the intervention as well as the
post survey. The data collected after the educational intervention represent the views of a
specific group and not the entire providers in the hospital. There are several parameters to
be evaluated for the metabolic screening which could lead to a poor result. The
psychiatric providers that prescribe medications depend on the nurses or other healthcare
workers to administer the screening tool. Button, Ioannidis, Morass, and Nosek (2013),
found that a convenience sample of 12 participants will affect the reliability of the study.
Summary
Overall the staff felt that the educational program increased their knowledge
about the screening and monitoring of MetS prior to taking the educational intervention.
Prior to initiation of the educational project, the pretest questionnaires show significant
variation in knowledge level psychiatric providers. After the educational program,
psychiatric providers had the basic knowledge and understanding of the importance of
screening psychiatric patients on antipsychotic medications for MetS. The educational
project was first presented to five expert panels for feedback using the Likert-type
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questionnaire. Then the education was presented to the psychiatric providers, the pre-and
posttest intervention signified improved knowledge about the importance of MetS
screening and its’ associated complications. Section 5 will include an analysis of self and
the dissemination plan for the project outcome.
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Section 5: Dissemination Plan
Introduction
The results of the educational project were positive and were disseminated to the
medical staff of the hospital, which comprised of nurse practitioners, psychiatrists, and
nursing staff. Based on the nature of the project, the appropriate audience for education
were psychiatrists, psychiatric nurse practitioners, and RNs. Dissemination to this group
of people was important to educate them to apply the evidence related to MetS in clinical
practice for improving patient outcomes. I will offer a presentation to the leaders of the
hospital and future presentation opportunities to present may arise as a result of the
leadership presentation. Educational settings, such as conferences or in-services at a
healthcare organization, would be appropriate for the dissemination of the project
information about clinical practice adherence to a global consensus guideline. Finally, the
ProQuest database is the avenue to disseminate the educational project for the broader
nursing profession.
Analysis of Self
Obtaining a terminal degree in nursing will be fulfilling for me both personally
and for my professional advancement. On a personal level, the scholarly project
challenged my intellectual ability and fulfilled one of my long-term goals, which was to
advance my nursing knowledge. Professionally, with the educational opportunity, I have
enhanced my leadership skills and gained knowledge in advancing nursing practice,
quality improvement, and healthcare policy.
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Nurses are the key to improving quality and providing cost-effective care to
enhance population health. As a practitioner and a scholar, prior to this project, my
experience in leading a healthcare team in system change was limited. The scholarly
project process provided me with the knowledge and skill sets to lead in any
organizational change. Engaging the stakeholders and end users early in the project was
the driving force that led to acceptance, assisted in achieving buy-in, and promoted
commitment to the project. Before the implementation of any change, it is imperative to
understand and identify the gap between recommended practice and the status quo. The
completion of the assessment assisted me in identifying the actual and potential barriers
to project implementation and the key staff who could assist to bridge the gap. After the
project, I consider myself an expert in assessing organizational needs, identifying system
issues, facilitating organization-wide changes in practice delivery, and assuming
leadership roles in every level of nursing.
Leadership
It is well known that mental health services have been an area that has received
less attention in medicine as compared to other health problems like cancer and
cardiovascular disease. My goals as a practitioner and leader are to continue advocating
for the integration of evidence-based practice and the global consensus for screening and
monitoring MetS among psychiatric patients. I planned to continue advancing my
profession by supporting research and creating a culture of evidence-based practice that
will support clinical decision making. I planned to continue initiating change in the
organization that is based on the research evidence and to integrate patient outcomes and
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safety as a driving force in quality and patient satisfaction. The scholarly project gave me
the perspective on the amount of work involved in project development and change in
policy, the relationship between research and practice, and the time it takes for research
results to be implemented in clinical practice. I planned to extend this project beyond my
doctoral education by presenting to local psychiatric nurse practitioner organizations in
the Midwestern part of the United States.
The challenges I experienced with the project were time management, balancing
project work, personal life, and my job. The solution I created for time management was
allocating a specific time frame for school work with no interference. I feel self-discipline
can be achieved by creating a schedule, managing time effectively, and developing an
effective habit. Scheduling a specific time for staff education was challenging. The
psychiatrists and the nursing staff were busy, the educational program took time away
from patient care. The insights gained from the scholarly educational project was the
amount of time and the dedication that goes into project development.
Summary
The purpose of this DNP project was to implement an educational intervention to
educate healthcare providers the importance of MetS on patients taking SGAs at an InPatient Psychiatric Center in the Midwestern part of the U.S. I conducted a needs
assessment in the Psychiatric Center, which indicated the gap-in-practice and lack of
metabolic monitoring and screening among patients taking SGAs. Lack of monitoring for
MetS increased the risk for the population served at the Psychiatric Center to develop
chronic health problems; making it imperative for psychiatrists and nursing staff to
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understand how to screen for MetS, manage, and refer as necessary. After the educational
intervention, nurses gained basic knowledge and an understanding of the importance of
metabolic screening. The project was effective as after the educational intervention, staff
indicated their willingness to screen for MetS according to the established consensus
guideline. Providers learned about the importance of screening for MetS and long-term
cost-effectiveness will be attained through early identification and treatment of resulting
chronic diseases, and avoidance of future complications and associated costs.
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Appendix A: Metabolic Syndrome Pamphlet
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Appendix B: Educational intervention Objectives
Goal of the project: Is to provide psychiatric clinicians with knowledge about
metabolic screening and monitoring of psychiatric patients taking antipsychotic
medications and the need to reduce metabolic risk. This education can lead to
improvement in the rate of screening and early intervention among this population.
Target Audience: Psychiatrists, Psychiatric-Mental health NPs, psychiatric
nurses, and Nurse Educators working with people with mental illness.
Learning Objectives:
1. Describe defining criteria of Metabolic syndrome and basic benefits of metabolic
screening for patients taking antipsychotic medications.
2. Describe the national established practice guideline for Metabolic screening and
3. monitoring of patients taking antipsychotic medications, mainly second-generation
antipsychotic (SGA) medications
4. Describe the risk factors associated with metabolic syndrome.
5. Describe gap in practice and barriers in implementation of metabolic screening
6. in psychiatric patients on antipsychotic medications.
7. Interprofessional Collaboration for improving patient and population health.
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Appendix C: ADA–APA Consensus Guideline
Baseline
screening
Personal/family
history
Weight and
height for
calculation of
BMI
Waist
circumference
at the level of
the umbilicus
Blood pressure
Fasting plasma
glucose
Fasting lipid
profile

4
8
12
Quarterly
weeks weeks weeks monitoring

X
X

Annual
monitoring

Every 5
years
monitoring

X
X

X

X

X

X

X

X
X

X
X

X

X

X
X
X

59
Appendix D: Pretest/Posttest (M-BACK) Questionnaire
Specialty Area: Please circle one specialty that identifies your profession.
Psychiatrist

Psychiatric- NP

Nurse Educator

Psychiatric Nurse Other ________

1. I have a good knowledge of metabolic syndrome.
1
Strongly Disagree

2
Disagree

3
Neutral

4
Agree

5
Strongly Agree

4
Agree

5
Strongly Agree

2. I understand how to screen for metabolic syndrome.
1
Strongly Disagree

2
Disagree

3
Neutral

3. My workload prevents me doing any health promotion activities with consumers.
1
2
3
4
5
Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

4. I understand the metabolic side-effect profiles of different neuroleptic medication.
1
Strongly Disagree

2
Disagree

3
Neutral

4
Agree

5
Strongly Agree

5. Metabolic health screening is an important part of my role as a mental health clinician.
1
Strongly Disagree

2
Disagree

3
Neutral

4
Agree

5
Strongly Agree
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Appendix E: Post Survey
1. The educational materials about metabolic syndrome, do you plan to apply this in
your job?
2. Will you consider adopting a structured system for monitoring metabolic syndrome
among patients on antipsychotic medications?
3. Will you consider a collaborative relationship with family practice to facilitate care
for patients on antipsychotic medications?
4. Was the room temperature and lighting comfortable?
5. Any other suggestion that should be included in the education of metabolic syndrome
6. Any suggestion/comment
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Appendix F: Metabolic Syndrome Screening Form
Patient Name __________________________ Date of Visit ___________
Metabolic syndrome considered positive if 3 or more risk criteria present
Measure

Risk Criteria

Abdominal
Obesity

Men
>40 inches
Women
> 35 inches

Triglycerides

≥150mg/dl

HDL
Cholesterol

Men < 40 mg/dl
Women < 50mg/dl

Blood Pressure

≥ 130/≥85 mmHg

Fasting lipid
glucose

≥ 100mg/dl

Wt./BMI

BMI ≥ 30

Baseline

_/_/_

_/_/_

_/_/_

_/_/_

_/_/_

Lipid Monitoring Results

Baseline

__/___/__

__/___/__

__/___/__

__/___/__

__/___/__

Total
LDL
HDL
TG

Serum Lipid Reference Range
Optimal/desired
Total
LDL

Near/above
desired

< 200
< 100

Borderline

High

200-239
130-159

≥ 240

Very high

≥ 190

100-129
HDL
TG

< 40 men
< 50 women
< 150

www.cqaimh.org/pdf/tool_metabolic.pd

≥ 60
150-199

200-499

≥ 500
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Appendix G: Approval Letter

To whom it may concern,
My name is Chika Okafor and I am a DNP student at Walden University, seeking
permission to use your M-Back questionnaire from your article. I am only going to use 5
questions. Could you please if I t is okay to use in my graduate project on educating
psychiatric providers about the importance of metabolic screening in patients taking
antipsychotic medications.
Thank you in advance for your consideration
Chika Okafor, MSN, ARNP, DNP Student, Walden University.
From: Andrew Watkins (South Eastern Sydney LHD)
<Andrew.Watkins@health.nsw.gov.au>
Sent: Thursday, January 17, 2019 4:17 PM
To: Okafor, Chika <Chika.Okafor@dmh.mo.gov>
Subject: RE: The M-BACK Questionnaire
Hi Chika,
Great that you are doing some work in this area. I am happy for you to use the M-BACK,
however, the M-BACK’s 16 question is divided into 4 sections Barriers, Attitudes,
Confidence and Knowledge each with 4 questions. Each section is validated individually,
but individual questions are not. I’m not sure which 5 questions you are using but it
might not be considered validated. I would consider using 1 or 2 sections if you want to
ensure that you are utilising a validated questionnaire.
I hope this is helpful, Kind regards
Andrew Watkins, Clinical Nurse Consultant, Clinical lead
Keeping the Body in Mind Program
26 Llandaff St, Bondi Junction 2022
9366 8610, https://www.seslhd.health.nsw.gov.au/keeping-body-min
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Appendix H: Flyer for Training

Presenter: Chika Okafor, DNP student, Walden University
Join us

Educating psychiatric providers about metabolic screening and
intervention among patients on antipsychotic medications.
Date: 6/3/19 Time: 5:00PM
Venue: RPC Education Center
Wow, refreshments will be provided
For more information, contact: Chika Okafor @ 8164622218
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Appendix I: Educational PowerPoint
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